Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne, positive-sense single-stranded RNA virus belonging to the Alphavirus genus and Togaviridae family. Its genome is approximately 12 kb long and encodes nonstructural proteins (nsP1-nsP4) involved in replication and mRNA capping, as well as structural proteins (Capsid, E1, E2, E3, and 6K) that form the viral particle. VEEV utilizes LDLRAD3 as its primary cellular receptor for entry. It is transmitted by mosquitoes and affects equids and small mammals, with humans as incidental hosts. Infection can cause flu-like symptoms or severe neurological complications. Epizootic strains (IAB, IC) are highly virulent, while enzootic strains (ID/IE) are typically less severe.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Venezuelan Equine Encephalitis Virus (VEEV).